Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(01): s00451802960
DOI: 10.1055/s-0045-1802960
Original Article

Diagnosing preclinical and clinical Alzheimer's disease with visual atrophy scales in the clinical practice

Karen Luiza Ramos Socher 
1   Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e do Comportamento, São Paulo SP, Brazil.
,
Douglas Mendes Nunes 
2   Universidade de São Paulo, Faculdade de Medicina, Instituto de Radiologia, Unidade de Neurorradiologia, São Paulo SP, Brazil.
,
Deborah Cristina P. Lopes 
1   Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e do Comportamento, São Paulo SP, Brazil.
,
Artur Martins Novaes Coutinho 
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Radiologia e Oncologia, Laboratório de Medicina Nuclear (LIM/43), São Paulo SP, Brazil.
,
Daniele de Paula Faria 
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Radiologia e Oncologia, Laboratório de Medicina Nuclear (LIM/43), São Paulo SP, Brazil.
,
Paula Squarzoni 
4   Universidade de São Paulo, Faculdade de Medicina, Departamento de Psiquiatria, São Paulo SP, Brazil
,
Geraldo Busatto Filho 
4   Universidade de São Paulo, Faculdade de Medicina, Departamento de Psiquiatria, São Paulo SP, Brazil
,
Carlos Alberto Buchpiguel 
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Radiologia e Oncologia, Laboratório de Medicina Nuclear (LIM/43), São Paulo SP, Brazil.
,
Ricardo Nitrini 
1   Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e do Comportamento, São Paulo SP, Brazil.
,
Sonia Maria Dozzi Brucki 
1   Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e do Comportamento, São Paulo SP, Brazil.
› Author Affiliations Funding The authors declare that Karen Luiza Ramos Socher received a research grant from the Alzheimer's Association (Alzheimer's Association Clinician Scientist Fellowship to Promote Diversity [AACSF-D] research grant number 1029216).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Visual atrophy scales from the medial temporal region are auxiliary biomarkers of neurodegeneration in Alzheimer's disease (AD). Therefore, they may correlate with progression from cognitively unimpaired (CU) status to mild cognitive impairment (MCI) and AD, and they become a valuable tool for diagnostic accuracy.

Objective To compare the medial temporal lobe atrophy (MTA) and entorhinal cortex atrophy (ERICA) scores measured through magnetic resonance image (MRI) scans as a useful method for probable AD diagnosis regarding clinical diagnosis and amyloid positron-emission tomography (PET).

Methods Two neurologists blinded to the diagnoses classified 113 older adults (age > 65 years) through the MTA and ERICA scores. We investigated the correlations involving these scores and sociodemographic data, amyloid brain cortical burden measured through PET imaging with (11)C-labeled Pittsburgh Compound-B (11C-PIB PET), and clinical cognitive status, in individuals diagnosed as CU (CU; N = 30), presenting mild cognitive impairment (MCI, N = 52), and AD patients (N = 31).

Results The inter-rater reliability of the atrophy scales was excellent (0.8–1) according to the Cohen analysis. The CU group presented lower MTA scores (median value: 0) than ERICA (median value: 1) scores in both hemispheres. The 11C-PIB-PET was positive in 45% of the sample. In the MCI and AD groups, the ERICA score presented greater sensitivity, and the MTA score presented greater specificity. The accuracy of the clinical diagnosis was sufficient and no more than 70% for both scores in AD.

Conclusion In the present study, we found moderate sensitivity for the ERICA score, which could be a better screening tool than the MTA score for the diagnosis of AD or MCI. However, none of the scores were useful imaging biomarkers in preclinical AD.

Keywords

Alzheimer Disease - Magnetic Resonance Imaging - Atrophy

Authors' Contributions

KLRS: study conception and design, and acquisition and analysis and/or interpretation of data; DMN: study conception and design, and acquisition and interpretation of data; DCPL: acquisition of data; AMNC: acquisition of data and critical review of the manuscript for important intellectual content; DPF and PS: acquisition of data and study supervision; GBF: acquisition of data and critical review of the manuscript for important intellectual content and study supervision; CAB and RN: study supervision; and SMDB: analysis and interpretation of data, critical review of the manuscript for important intellectual content, and study supervision.


Editor-in-Chief: Hélio A. G. Teive.


Associate Editor: Leonardo Cruz de Souza.




Publication History

Received: 01 May 2024

Accepted: 13 October 2024

Article published online:
28 February 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Karen Luiza Ramos Socher, Douglas Mendes Nunes, Deborah Cristina P. Lopes, Artur Martins Novaes Coutinho, Daniele de Paula Faria, Paula Squarzoni, Geraldo Busatto Filho, Carlos Alberto Buchpiguel, Ricardo Nitrini, Sonia Maria Dozzi Brucki. Diagnosing preclinical and clinical Alzheimer's disease with visual atrophy scales in the clinical practice. Arq Neuropsiquiatr 2025; 83: s00451802960.
DOI: 10.1055/s-0045-1802960
 

  • References

  • 1 Risk reduction of cognitive decline and dementia. World Health Organization. Updated February 5, 2019. Accessed July 4, 2020. https://www.who.int/publications/i/item/risk-reduction-of-cognitive-decline-and-dementia
  • 2 Boff MS, Sekyia FS, Bottino Cde C. Revisão sistemática sobre prevalência de demência entre a população brasileira. Rev Med (São Paulo) 2015; 94 (03) 154-161
    CrossrefSearch in Google Scholar
  • 3 César KG, Brucki SM, Takada LT. et al. Prevalence of Cognitive Impairment Without Dementia and Dementia in Tremembé, Brazil. Alzheimer Dis Assoc Disord 2016; 30 (03) 264-271
    CrossrefPubMedSearch in Google Scholar
  • 4 Chaves ML, Camozzato AL, Godinho C, Piazenski I, Kaye J. Incidence of mild cognitive impairment and Alzheimer disease in Southern Brazil. J Geriatr Psychiatry Neurol 2009; 22 (03) 181-187
    CrossrefPubMedSearch in Google Scholar
  • 5 Nitrini R, Caramelli P, Herrera Jr E. et al. Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2004; 18 (04) 241-246
    PubMedSearch in Google Scholar
  • 6 Brucki SMD. Epidemiology of mild cognitive impairment in Brazil. Dement Neuropsychol 2013; 7 (04) 363-366
    CrossrefPubMedSearch in Google Scholar
  • 7 Jack Jr CR, Andrews JS, Beach TG. et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement 2024; 20 (08) 5143-5169 ; Advance online publication
    CrossrefPubMedSearch in Google Scholar
  • 8 Harper L, Fumagalli GG, Barkhof F. et al. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain 2016; 139 (Pt 4): 1211-1225
    CrossrefPubMedSearch in Google Scholar
  • 9 Parra MA, Baez S, Allegri R. et al. Dementia in Latin America: Assessing the present and envisioning the future. Neurology 2018; 90 (05) 222-231
    CrossrefPubMedSearch in Google Scholar
  • 10 Scheltens P, Leys D, Barkhof F. et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55 (10) 967-972
    CrossrefPubMedSearch in Google Scholar
  • 11 Enkirch SJ, Traschütz A, Müller A. et al. The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology 2018; 288 (01) 226-333
    CrossrefPubMedSearch in Google Scholar
  • 12 Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56 (03) 303-308 Erratum in: Arch Neurol 1999;56(6):760
    CrossrefPubMedSearch in Google Scholar
  • 13 Bondi MW, Edmonds EC, Jak AJ. et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis 2014; 42 (01) 275-289
    CrossrefPubMedSearch in Google Scholar
  • 14 Coutinho AM, Busatto GF, de Gobbi Porto FH. et al. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. [published correction appears in Eur J Nucl Med Mol Imaging. 2020 Jun 26;] Eur J Nucl Med Mol Imaging 2020; 47 (11) 2666-2680
    CrossrefPubMedSearch in Google Scholar
  • 15 Pfeffer RI, Kurosaki TT, Harrah Jr CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37 (03) 323-329
    CrossrefPubMedSearch in Google Scholar
  • 16 Busatto GF, de Gobbi Porto FH, Faria DP. et al. In vivo imaging evidence of poor cognitive resilience to Alzheimer's disease pathology in subjects with very low cognitive reserve from a low-middle income environment. Alzheimers Dement (Amst) 2020; 12 (01) e12122
    CrossrefPubMedSearch in Google Scholar
  • 17 Camus V, Payoux P, Barré L. et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012; 39 (04) 621-631
    CrossrefPubMedSearch in Google Scholar
  • 18 Clark CM, Pontecorvo MJ, Beach TG. et al; AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. [published correction appears in Lancet Neurol. 2012 Aug;11(8):658] Lancet Neurol 2012; 11 (08) 669-678
    CrossrefPubMedSearch in Google Scholar
  • 19 Yamane T, Ishii K, Sakata M. et al; J-ADNI Study Group. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging 2017; 44 (05) 850-857
    CrossrefPubMedSearch in Google Scholar
  • 20 Faria DP, Duran FL, Squarzoni P. et al. Topography of 11C-Pittsburgh compound B uptake in Alzheimer's disease: a voxel-based investigation of cortical and white matter regions. Br J Psychiatry 2019; 41 (02) 101-111
    CrossrefPubMedSearch in Google Scholar
  • 21 Klunk WE, Engler H, Nordberg A. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55 (03) 306-319
    CrossrefPubMedSearch in Google Scholar
  • 22 Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70 (11) 960-969
    CrossrefPubMedSearch in Google Scholar
  • 23 Ferretti C, Sarti FM, Nitrini R, Ferreira FF, Brucki SMD. An assessment of direct and indirect costs of dementia in Brazil. PLoS One 2018; 13 (03) e0193209
    CrossrefPubMedSearch in Google Scholar
  • 24 Wei M, Shi J, Ni J. et al. A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer's disease in a Chinese population. BMC Geriatr 2019; 19 (01) 59
    CrossrefPubMedSearch in Google Scholar
  • 25 Nelson PT, Head E, Schmitt FA. et al. Alzheimer's disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 2011; 121 (05) 571-587
    CrossrefPubMedSearch in Google Scholar
  • 26 Nelson PT, Dickson DW, Trojanowski JQ. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 2019; 142 (06) 1503-1527
    CrossrefPubMedSearch in Google Scholar
  • 27 Rowe CC, Ellis KA, Rimajova M. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31 (08) 1275-1283
    CrossrefPubMedSearch in Google Scholar
  • 28 Jack Jr CR, Bennett DA, Blennow K. et al; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14 (04) 535-562
    CrossrefPubMedSearch in Google Scholar
  • 29 Knopman DS, Jack Jr CR, Wiste HJ. et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 2013; 73 (04) 472-480
    CrossrefPubMedSearch in Google Scholar
  • 30 Wirth M, Villeneuve S, Haase CM. et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013; 70 (12) 1512-1519
    CrossrefPubMedSearch in Google Scholar